Hass Corp (450330) Fair Value & Analysis
Healthcare · KR · Market cap 33.0B KRW
Fair value as of: Jul 22, 2026
From 14 valuation models · updated 19 days ago
Share price −7.5% over the past month.
Below-average quality, and screening another 23% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (4,225 KRW). The favourable scenario is already priced in.
- Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
25‑month range 3,790 KRW – 16,819 KRW · fair‑value band 2,545 KRW – 4,225 KRW · the 4,415 KRW price screens above the 3,394 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Hass Corp (450330) currently trades at 4,415 KRW, while our model-based Fair Value estimate is 3,394 KRW, implying the stock looks roughly 23.1% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Hass Corp generated revenue of 16.6B KRW at a net margin of 8.5%. Revenue declined 0.5% year over year. It earns a return on equity of 3.3%. Net debt stands at 4.4B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 2,545 KRW (bear case) to 4,225 KRW (bull case); at 4,415 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 52% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -23%, 450330 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Asset-Based (4,008 KRW) versus Earnings-Based (1,781 KRW). Highest evidence: Residual Income (76).
Notify me when 450330 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 40 · Market factors (momentum, volatility) 21
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hass Corp. manufactures and sells dental medical devices. Its CAD/CAM systems include Amber Mill, a machinable dental glass-ceramic blocks made of lithium disilicate; Amber Mill Direct, a CAD/CAM-based millable lithium disilicate block; Amber Mill H, a CAD/CAM block using nano-crystalline ceramics particle; Amber Mill Q, an implant abutment solution; and …
Full company description
Hass Corp. manufactures and sells dental medical devices. Its CAD/CAM systems include Amber Mill, a machinable dental glass-ceramic blocks made of lithium disilicate; Amber Mill Direct, a CAD/CAM-based millable lithium disilicate block; Amber Mill H, a CAD/CAM block using nano-crystalline ceramics particle; Amber Mill Q, an implant abutment solution; and Amber Mill Meso, a lithium disilicate-based block for implant prosthese. The company's heat-pressing systems comprise Amber Press, a lithium disilicate-based press ingots; Amber Press Master, a lithium disilicate-based high fusion press ingots; and Amber LiSi-POZ and Amber LiSi-POM for lithium disilicate-based press on zirconia. In addition, it offers Amber Vest, an ultra-fine phosphate bound investment for pressable dental ceramics; COCO Lux, a mobile dental photography solution; Selection Tip, a shade matching solution; and Amber Glow, a polish for zirconia, lithium disilicate, porcenlain, and composite. The company was founded in 2008 and is headquartered in Gangneung-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hass Corp reported revenue of 16.6B KRW in FY2025 versus 12.6B KRW in FY2021, a compound +7.1%/yr. Reported net income was 1.5B KRW in FY2025, compounding −0.2%/yr from FY2021.
450330 screens 23% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Hass Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hass Corp (450330) overvalued or undervalued?
What is the fair value of 450330?
What is the quality score of 450330?
What is the revenue of Hass Corp (450330)?
What is the net profit margin of 450330?
Does Hass Corp pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hass Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.